Northern Alliance Advanced Therapies Treatment Centre
The Northern Alliance Advanced Therapy Treatment Centre (NA-ATTC), formally established in March 2018, is a consortium of twenty industry, NHS and academic organisations led by Newcastle Hospitals and the Scottish National Blood Transfusion Service (SNBTS). The purpose of the centre is to develop the systems and infrastructure required to support the delivery of cell and gene therapies with the ultimate aim of increasing patient access to advanced therapy medicinal products (ATMPs) on a national level.
NA-ATTC’s vision is to increase patient access to advanced therapy medicinal products (ATMPs) regionally and nationally by growing a cost-effective clinical delivery pathway which meets the needs of the providers of advanced therapy products. The centre has a patient reach of circa 15 million spanning the North of England and Scotland and is working across two healthcare systems.
The centre will focus on all elements of the clinical delivery pathway from procurement of starting materials, near patient GMP, distribution and administration through to delivery of clinical trials and adoption and reimbursement across a range of advanced therapies and indications. This will entail the participation and collaboration of nurses, medical clinicians, hospital pharmacists, NHS managers, clinical commissioners and companies.
Please view our video which explains more about the NA-ATTC, our vision and how we plan to achieve this along with our Partners as well as our results so far:
Location
The NA-ATTC works across the north of England (Leeds and Newcastle upon Tyne) and Scotland.
Our partners
Academic Health Science Network for the North East and North Cumbria (AHSN NENC)
www.ahsn-nenc.org.uk
Russ Watkins, Commercial Director
Donna Smith, Marketing
Achilles Therapeutics
Dr Shreenal Patel, SVP Clinical & Supply Chain Operations
Alcyomics Ltd
www.alcyomics.com
Professor Anne Dickinson, Founder and Director
Autolus Therapeutics
Christopher Vann Senior Vice President, Chief Operating Officer
Helen Delahaye, Project Manager
Chiesi Limited
http://chiesi.uk.com/rare-diseases
Julie De-Almeida, Head of Market Access UK & Ireland
Tom Chubb, Rare Disease Manager
Cytiva
https://www.cytivalifesciences.com/en/us
Dr John G Morris, Chief Executive Officer
Bill Shingleton, Alliances Manager
Datatrial
www.datatrial.com
Julie Wright, Commercial Director
Jamie Pollard, Head of Software Development
Find out more about our work with Datatrial here.
Fisher Bioservices
www.fisherbioservices.com
Neil Ridley, Consultant Project Director
Luke Wilson, Lead Account Manager
Sandip Kumar, Project Manager, Client Services
NHS Greater Glasgow and Clyde
www.nhsggc.org.uk
Dr David Irvine, Consultant Haematologist
Dr Samantha Carmichael, Lead Pharmacist – Clinical Trials/R&D
Melanie McColgan, General Manager, Specialist Oncology and Clinical Haematology
Leeds Teaching Hospitals NHS Trust
www.leedsth.nhs.uk
Dr Christopher Herbert, Director of Operations for Research and Innovation
Professor Gordon Cook, Professor of Haematology and Myeloma Studies
Dr Beki James, Consultant Paediatric Haematologist
Milteyni Biotec
www.milteynibiotec.com
Michele Giroux, UK General Manager
Newcastle University
www.ncl.ac.uk
https://www.ncl.ac.uk/icm/research/
https://www.ncl.ac.uk/ctf/
Professor Jim Shaw, Professor of Regenerative Medicine
Professor Anne Dickinson, Strategic Research Adviser
Dr Mark Jarvis, Assistant Director of Pharmacy – Advanced Therapies
NHS Blood and Transplant
www.nhsbt.nhs.uk
Jon Smythe, Head of Cellular and Molecular Therapies
Dr Sandeep Kumar, Cell Therapy Advanced Specialist
NHS Lothian
www.nhslothian.scot.nhs.uk
Professor Timothy Walsh, Head of Section/Lead of Edinburgh Critical Care Research Group, R&D Director – NHS Lothian
The Newcastle upon Tyne Hospitals NHS Foundation Trust
www.newcastle-hospitals.org.uk
Neil Watson, Clinical Director of Pharmacy and Medicines Management and Co-Director of the NA-ATTC
Dr Finn Willingham, Operations Manager, NA-ATTC
David Caulfield, Assistant Director of Pharmacy, QA
Anne Black, Regional QA Specialist/Lead for Newcastle Therapeutics
pHion Therapeutics
Darach Neeson, Chief Operating Officer
RoslinCT
www.roslinct.com
Janet Downie, Chief Executive Officer
Scottish National Blood Transfusion Service
www.scotblood.co.uk
Professor Marc Turner, Medical Director SNBTS and Co-Director of the NA-ATTC
Professor John Campbell, Associate Director – Tissues, Cells and Advanced Therapeutics
Ewan Morrison, Director of Pharmacy, National Services Scotland
Sheffield Teaching Hospitals NHS Foundation Trust
Professor Simon Heller, R & D Director
Dr Dipak Patel, Research & Innovation Manager
TrakCel
www.trakcel.com
Dr Matthew Lakelin, Chief Scientific Officer
Find out more about our work with TrakCel here.
University of Edinburgh
https://www.ed.ac.uk/
http://www.crm.ed.ac.uk/research/group/liver-stem-cells-and-regeneration
https://www.cvs.ed.ac.uk/research
Prof Stuart Forbes, Director, Scottish Centre for Regenerative Medicine (SCRM), WP3 Co-Lead, Clinical Advisory Group Clinician Scientist Lead
Prof Andy Baker, Scientific Advisor
Lisa Wotherspoon, Advanced Therapies Clinical Trial Coordinator
University of Glasgow
Professor Stuart Nicklin, of Cardiovascular Molecular Therapy
VascVersa
Dr Christina O’Neill, Chief Executive Officer and Founder
Professor Alan Stitt, Scientific Consultant
Professor Reinhold Medina, Scientific Consultant
World Courier
www.worldcourier.com
Kelly Frend , WEMEA Specialty Services Manager
Support was provided by Cell Medica (www.cellmedica.com) for the first half of the project.
Leadership team
Professor Neil Watson, Clinical Director of Pharmacy and Medicines Optimisation and Co-Director of the NA-ATTC
Marc Turner, Co-Director
Finn Willingham, Operations Manager
Michael Whitaker, Steering Board Chair (Galen Biomed Ltd.)
Jim Shaw, Clinical Advisory Group Chair (Newcastle University)
Christopher Herbert, Leeds Teaching Hospitals NHS Foundation Trust
Andy Baker, Scientific Advisor (University of Edinburgh)
Christopher Vann, Senior Vice President, Chief Operating Officer, Autolus
Governance – Terms of Reference
The NA-ATTC is overseen by governance structures including a Steering Board, made up of representatives from each Partner Organisation, an Executive Team as detailed above, and a Clinical Advisory Group and Industry Advisory Group. Further details of these structures and their Terms of Reference are available below.
NA-ATTC Steering Board:
NA-ATTC Executive Team:
NA-ATTC Clinical Advisory Group:
Clinical Advisory Group Membership
NA-ATTC Trial Coordination Unit